Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 30, 2023 12:00 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences Announces Completion of Business Combination With Beijing Continent Pharmaceuticals and Implementation of Name Change and Reverse Stock Split

The combined company will operate as “Gyre Therapeutics, Inc.” with its common stock traded on Nasdaq under trading symbol “GYRE” effective Tuesday, October 31, 2023 SAN DIEGO, Oct. 30, 2023 (GLOBE...
February 28, 2023 08:00 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences Provides Corporate Update

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Catalyst Biosciences Inc. (NASDAQ: CBIO) (“Catalyst” or “the Company”) today provided two corporate updates. In connection with the...
December 27, 2022 07:00 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences Completes First Steps in Reverse Merger Plan

Acquires F351, a Phase 3 Drug to Treat Fibrosis Will Acquire Controlling Interest in Continent, a China-Based Commercial Pharma Company, from the GNI Group in Subsequent Transaction Announces $7.5...
September 01, 2022 16:05 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences, Inc. Announces September 21, 2022 as the Ex-Dividend Date for Special Cash Dividend of $1.43 per share

SOUTH SAN FRANCISCO, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (“Catalyst,” the “Company” or “we”) today announced that the ex-dividend date for the...
August 25, 2022 08:00 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences, Inc. Declares Special Cash Dividend of $1.43 per share

SOUTH SAN FRANCISCO, Calif., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (“Catalyst,” the “Company” or “we”) today announced that the Board of Directors has declared...
August 19, 2022 08:00 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences, Inc. Announces Dismissal of JDS1 Litigation

SOUTH SAN FRANCISCO, Calif., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (“Catalyst,” the “Company” or “we”) today announced that JDS1, LLC, one of the Company’s...
August 15, 2022 16:05 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences Reports Second Quarter 2022 Operating & Financial Results

SOUTH SAN FRANCISCO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (the “Company” or “we”) today announced its operating and financial results for the second...
August 10, 2022 12:46 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences Announces Withdrawal of JDS1 Nominations to the Board

SOUTH SAN FRANCISCO, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (the “Company,” “Catalyst” or “we”) announced that it has received a notice from JDS1, LLC...
August 03, 2022 08:00 ET | Source: Catalyst Biosciences, Inc.

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Catalyst Stockholders Vote “FOR” All of the Company’s Nominees on the WHITE Proxy Card

ISS and Glass Lewis Highlight That Stockholders Are Best Served by Allowing the Incumbent Board to Pursue Its Cash Distribution Plan Catalyst Urges Stockholders to VOTE “FOR” All of the Company’s...
August 01, 2022 08:30 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences Publishes New Investor Presentation

Provides Details on Current Board’s Cash Distribution Plan and Efforts to Maximize the Amount of Cash Available for Distribution Company Commits to Distributing $45 Million to Stockholders in an...